DLBCL is an aggressive type of non-Hodgkin’s lymphoma that is curable with immunochemotherapy in 50% to 60% of cases.1 For patients who fail 1L therapy, prognoses are poor, worsening with each line of therapy as the chance for cure or long-term disease-free survival diminishes.2,3
Current regimens for later lines are typically limited in ability to induce durable complete responses or involve complex and onerous multiagent and multi-infusion regimens that are associated with significant toxicity.
Determining the optimal treatment pathway for each patient involves weighing the quality of a potential response against the risk for long-term and debilitating treatment-related complications.4
Novel targeted therapies that offer a chance for quickly seen complete and durable response and that are less burdensome may reset expectations for continuing active therapy longer.
References: 1. Liu Y, Barta SK. Am J Hematol. 2019;94:604-616. 2. Crump M, Neelapu SS, Farooq U, et al. Blood. 2017;130:1800-1808. 3. Klink AJ, Nabhan C, Lee CH, et al. J Clin Pathways. 2020;6:44-53. 4. Hodgson DC. Clin Adv Hematol Oncol. 2015;13:103-112.